@GvHD_Meade @CIBMTR @ASTCT @BMTCTN You can find me on the other site. :) I’ve no intentions currently to post on this app again.

Posting from #tandem25 at the other place, for those interested.

I’ll be over here for #ASH24, if you’re interested. Cheers

It was about choosing to stave off authoritarianism and preserve the republic vs suicidally steer into oncoming traffic and give up what the Founders of this country envisioned for our future. We are lost. (6/6)

It will take most of my children’s lives to correct, if we as a nation find the will to correct course. I’m not sure it will happen, sadly, unless we break free from a two party system that has lead to almost complete stagnation at the legislative level. (4/n)

But I’m sad about what Trump’s second win says about America. America voted against the rule of law. America voted against civil discourse. America voted against respect for diversity. America voted against respect for science. (2/n)

RT @sarahkendzior: Trump was not an aberration but a culmination of decades of corruption and elite criminal impunity. He rose through a da…

RT @sarahkendzior: If Dems and other officials do not hold the perperators of past admin crimes accountable *and* tackle the structural iss…

“Theoretically.” Way to go, America…

Other things I could very well have put on my costume this year…

Election 2024—what a dumpster fire. If you follow me on IG, you know how I feel. Vote KH for all the reasons she’s right. And after the election we’ll fight like hell to chg US policy in the M.E. No chance for better w DJT, who mustn’t be allowed reigns of power again.✌🏻Happy 🎃

First time to HEMO Congress. Sooo many people!! Feels bigger than EHA. 🤯#hemo24 #eunãofaloportuguês

#SOHO24 Jayakumar (PGY2 at the podium 👏🏻): a nationwide analysis of aspirin effects in leukemia patients. Looked at >1.6M leukemia hospitalizations, 11.2% on ASA. ASA assoc w lower risks or VTE and, interestingly, bleeding and septic shock and shorter length of stay.

#SOHO24 Subklewe: beautiful model for development of immunotherapy in AML as definitive therapy or bridge to alloHCT. (Stellar talk!! Very hard to keep up with so much data presented…)

#SOHO24 Subklewe: CD45 edited CAR-T could, in theory, be a pan-heme malignancy immunotherapy.

#SOHO24 Subklewe: CAR-T and CAR-NK therapies under development for AML.

#SOHO24 Subklewe: using BispAb in lower disease burden (ie, MRD) may be best approach. NK cell therapies also be tested in MRD setting.